AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01923831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
Study NCT01923831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
Study NCT01954160 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Symplicity Renal Denervation
Description: Renal denervation
Study NCT04304742 — intervention group
Intervention type: PROCEDURE
Intervention: hip standard radiography/ CT scan/ MRI
Description: hip standard radiography/ CT scan/ MRI
Study NCT03584061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
Study NCT03928158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ 696
Description: 50-100-200 mg tablet
Study NCT03928158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40-80-160 mg tablet
Study NCT01039870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: postoperative pain is controlled with local analgesics delivered via PVB
Study NCT01039870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural analgesia
Description: postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
Study NCT01941693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
Study NCT01941693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
Study NCT00699764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine- adjuvanted GSK208141
Description: Intramuscular injection, 3 doses
Study NCT00699764 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Intramuscular injection, 3 doses
Study NCT03969732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. amyloid PET；2. T807 PET
Description: 1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)
Study NCT02211625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label TRV734 125 mg
Description: 125 mg
Study NCT02211625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRV734 blinded
Description: blinded, multiple ascending dose
Study NCT02211625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR 10 mg
Study NCT02211625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TRV734-matched and oxycodone placebo
Study NCT04435587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: 3 days of once daily oral ivermectin 600mcg/kg/d
Study NCT04435587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined ART/hydroxychloroquine
Description: 1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days
Study NCT01028885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation
Study NCT01028885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT01028885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Study NCT01441440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
Study NCT01248234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
Study NCT01028885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Study NCT01028885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Study NCT03151343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin tablet
Study NCT03151343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill, visually identical to active comparator
Study NCT03945214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation
Study NCT03945214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating
Description: A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
Study NCT03945214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation + healthy eating
Description: 10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
Study NCT02847975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Sodium nitrate will be ingested orally
Study NCT03108274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study NCT01248234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03774381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve B-3
Description: 160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
Study NCT03774381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 160 mg of placebo is orally administered per day for 12 weeks.
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03219502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03219502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS
Study NCT03219502 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study NCT03108274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup.
Study NCT01248234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Etomidate
Description: Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
Study NCT03389126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
Study NCT04329611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: COVID19
Study NCT04329611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: COVID19
Study NCT02929095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Study NCT02929095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Study NCT02929095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
Study NCT02929095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Description: One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Ertugliflozin
Description: One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: 1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
Study NCT01958671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glimepiride
Description: Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
Study NCT02126904 — intervention group
Intervention type: DRUG
Intervention: IVA group
Study NCT04492956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Oral tablet
Study NCT04492956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT01798784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 1
Description: Daily sweepstake conditional on daily medication adherence
Study NCT01798784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 2
Description: Daily sweepstake conditional on daily medication adherence
Study NCT01798784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 3
Description: Daily sweepstake conditional on daily medication adherence
Study NCT00630578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
Study NCT00630578 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
Study NCT01957150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Study NCT01957150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Study NCT01139294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: 1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
Study NCT01879631 — intervention group
Intervention type: PROCEDURE
Intervention: radial keratotomy
Study NCT04329299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood-based biomarkers analyses
Description: Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
Study NCT03710044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.
Study NCT01986374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG is introduced
Description: must have good blastocysts
Study NCT05684003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise based injury-prevention program
Description: Neuromuscular exercise based injury-prevention program
Study NCT03342235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photorefractive Keratectomy (PRK)
Description: Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
Study NCT03342235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching 2 hours per day
Description: Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
Study NCT03342235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser System
Description: Excimer Laser System for use in photorefractive keratectomy.
Study NCT03668951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine buccal
Description: DEX 2 mcg/kg buccal
Study NCT03668951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intranasal
Description: DEX 3 mcg/kg intranasal
Study NCT03668951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intranasal
Description: DEX 4 mcg/kg intranasal
Study NCT01885351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCRCS+Prefs
Description: Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.
Study NCT01885351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCRCS+Prefs+Barriers
Description: Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers.
Study NCT01073345 — intervention group
Intervention type: PROCEDURE
Intervention: Portal venous pressure
Description: Portal venous pressure is measured by invasive means using an arterial canula
Study NCT02573740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-957
Study NCT02573740 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02939690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVC
Description: UVC insertion depth calculated by \[(3× birth weight (Kg) + 9)/2+1)\]
Study NCT02939690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVC
Description: UVC insertion depth calculated by umbilicus to nipple distance-1
Study NCT02939690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT02939690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT03930251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-Based Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
Study NCT03930251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial-Remote Cognitive Remediation
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
Study NCT01024777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
Study NCT01024777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
Study NCT02090231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS, Magstim Rapid2
Description: 5 Hz rTMS
Study NCT02090231 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS, Magstim Rapid2
Description: 5 Hz rTMS